Drug-drug interactions: Antiretroviral drugs and recreational drugs

Recent Patents on CNS Drug Discovery

Volumn 9, Issue 3, 2014, Pages 153-163

  Staltari, Orietta ^a   Leporini, Christian ^a   Caroleo, Benedetto ^b   Russo, Emilio ^a,b   Siniscalchi, Antonio ^d   De Sarro, Giovambattista ^a,b,c   Gallelli, Luca ^a  

^a AO Mater Domini   (Italy)

^b Operative Unit of Infectious Disease AO MaterDomini Catanzaro   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^d Department of Neurology Annunziata Hospital   (Italy)

Author keywords

Adverse drug reactions; Antiretroviral therapy; Clinical failure; Drug drug interactions; Recreational drugs

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ABACAVIR; ALCOHOL; AMPHETAMINE DERIVATIVE; ANTIRETROVIRUS AGENT; CANNABINOID; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; COCAINE; CYTOCHROME P450; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; GABAERGIC RECEPTOR AFFECTING AGENT; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INTEGRASE INHIBITOR; LAMIVUDINE PLUS STAVUDINE; LYSERGIDE; METHADONE; MULTIDRUG RESISTANCE PROTEIN; OPIATE; PHENCYCLIDINE; PROTEINASE INHIBITOR; PSYCHEDELIC AGENT; RECREATIONAL DRUG; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; UNINDEXED DRUG; ZIDOVUDINE; STREET DRUG;

ARTICLE; COMORBIDITY; DRUG ALCOHOL INTERACTION; DRUG EXCRETION; DRUG INTERACTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; HIV INFECTIONS;

ANTI-RETROVIRAL AGENTS; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; STREET DRUGS;

EID: 84930899864     PISSN: 15748898     EISSN: 22123954     Source Type: Journal    
DOI: 10.2174/1574889809666141127101623     Document Type: Article

References (141)

1. [1] Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365(6): 493-505.
2. [2] Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375(9731): 2092-8.
3. [3] Rupérez, J.M., Pardo, J.C., Rius, L.E., Maimó, R.B. Process for the preparation of abacavir. US8097723B2 (2012).
4. [4] Chu, D., Zhang, D. A process for preparing didanosine. WO2006128328A1 (2006).
5. [5] Bartra, S.M., Berenguer, M.R., Solsona, R.J.G. Process for obtaining emtricitabine. WO2011120927A1 (2011).
6. [6] Parthasaradhi, R.B., Srinivas, R.M., Venkateswar, R.P., Vanaja, K.M. Solid oral dosage forms of lamivudine. WO2010137027A1 (2010).
7. [7] Ray, P.C., Tummanapalli, J.M.C., Gorantla, S.R. Process for the large scale production of Stavudine. US8026356B2 (2011).
8. [8] Vasireddy, U.M.R., Vellanki, S.R.P., Balusu, R.B., Bandi, N.D.R., Jujjavarapu, P.K., Ginjupalli, S.R., Pilli, R.K. Process for the preparation of Tenofovir. US8049009B2 (2011).
9. [9] Jones, H.P., Mackey, R.J., Gamlen, M.J.D. Controlled release formulations containing zidovudine. US4917900A (1990).
10. [10] Martino, A.C., Bates, A.H., Morozowich, W., Lee, E.J. Delavirdine high strength tablet formulation. US6177101B1 (2001).
11. [11] Udit, B., Higgins, R.J., Katdare, A.V., Thompson, K.C. Efavirenz compressed tablet formulation. WO1999061026A1 (1999).
12. [12] De Corte, B., De Jonge, M.R., Heeres, J., Ho, C.Y., Janssen, P.A.J., Kavash, R.W., Koymans, L.M.H., Kukla, M.J., Ludovici, D.W., Aken, K.J.A.V. Nitrogen compounds such as 4-((4-amino-5- bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2 - pyrimidinyl)amino)benzonitrile, used as protease inhibitors for prophylaxis of viral diseases. US7037917B2 (2006).
13. [13] Hargrave, K.D., Proudfoot, J.R., Adams, J., Grozinger, K.G., Gunther, S.D., Engel, W., Trummlitz, G., Eberlein, W. 5,11- dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection. US5366972A (1994).
14. [14] Guillemont, J.E.G., Palandjian, P., De Jonge, M.R., Koymans, L.M.H., Vinkers, H.M., Daeyaert, F.F.D., Heeres, J., Aken, K.J.A.V., Lewi, P.J., Janssen, P.A.J. Prevention reproduction of virus. US7125879B2 (2006).
15. [15] Jones, L.H., Mowbray, C.E., Price, D.A., Selby, M.D., Stupple, P.A. Pyrazole derivatives for treating HIV. WO2002085860A1 (2002).
16. [16] Gadakh, S.K., Rekula, R.S., Sudalai, A. A process for synthesis of syn azido epoxide and its use as intermediate the synthesis of amprenavir & saquinavir. WO2013105118A1 (2013).
17. [17] Fassler, A., Bold, G., Lang, M., Bhagwat, S., Schneider, P. Antiretroviral hydrazine derivatives. US5753652A (1998).
18. [18] Mizhiritskii, M., Marom, E. Process for the preparation of darunavir and darunavir intermediates. EP2528923A1 (2012).
19. [19] Xu, J., Ye, M., Chen, B., Xu, Q. Preparation method of fosamprenavir derivatives and relevant intermediate thereof. US20130225839A1 (2013).
20. [20] Lui, C.Y., Ostovic, D., Katdare, A.V., Stelmach, C. Dry granulation formulation for an HIV protease inhibitor. US6645961B1 (2003).
21. [21] Reddy, B.P., Reddy, K.R., Reddy, R.R., Reddy, D.M., Reddy, K.S.C. Novel polymorphs of lopinavir. US20110294839A1 (2011).
22. [22] Petersen, C., Pun, E.F.C. Regimen of administration for nelfinavir. WO2004069251A1 (2004).
23. [23] Parthasaradhi, R.B., Khadgapathi, P., Kamalakar, R.G. Ritonavir compositions. WO2013128467A1 (2013).
24. [24] Parthasaradhi, R.B., Rathnakar, R.K., Raji, R.R., Muralidhara, R.D., Subash, C.R.K., Srinivasa, R.B. Novel polymorphs of saquinavir. EP2398773A2 (2011).
25. [25] Klingler, F., Steigerwald, M., Ehlenz, R. Enantioselective hydrogenation of intermediates in the synthesis of tipranavir. US20040224990A1 (2004).
26. [26] Reddy, B.P., Khadgapathi, P., Reddy, G.K. Pharmaceutical compositions of raltegravir, methods of preparation and use thereof. WO2012147101A2 (2012).
27. [27] Vellanki, S.R.P., Dhake, V.N., Ravi, S., Nuchu, R., Puliyala, R. Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts. WO2010137032A2 (2010).
28. [28] Parthasaradhi, R.B., Khadgapathi, P., Kamalakar, R.G., Rama, R.N. Pharmaceutical compositions of Maraviroc and process for the preparation thereof. WO2012114352 (2012).
29. [29] Kuppanna, A., Komma, R.M.B.R., Datta, D. An improved process for the preparation of enfuvirtide. WO2011095989A2 (2011).
30. [30] Gruber VA, McCance-Katz EF. Methadone, buprenorphine, and street drug interactions with antiretroviral medications. Curr HIV/AIDS Rep 2010; 7(3): 152-60.
31. [31] Weg, S.L. Administration of ketamine to manage pain and to reduce drug dependency. WO1997007750A1 (2001).
32. [32] Gonzales, G., Manfredi, P. Oral transmucosal methadone. US20050065175A1 (2005).
33. [33] Philippe, B., Antonio, S., Francis, V. Stable oral pharmaceutical compositions of buprenorphine and derivatives. WO2005117838A1 (2005).
34. [34] Liang, L., Shah, N., Bhatt, P.P., Ibrahim, S. Controlled release compositions of gamma-hydroxybutyrate. US20120231085A1 (2012) and US8193211B2 (2012).
35. [35] Moody DE. Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine. Expert Opin Drug Metab Toxicol 2013; 9(6): 675-97.
36. [36] Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Rev Clin Pharmacol 2013; 6(3): 249-69.
37. [37] McCance-Katz EF. Drug interactions associated with methadone, buprenorphine, cocaine, and HIV medications: implications for pregnant women. Life Sci 2011; 88(21-22): 953-8.
38. [38] McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addictions/ Am Acad Psychiatrists Alcoholism Addictions 2010; 19(1): 4-16.
39. [39] Palleria C, Di Paolo A, Giofrè C, Caglioti C, Leuzzi G, Siniscalchi A, et al. Pharmacokinetic drug-drug interactions and their implication in clinical management. J Res Med Sci 2013; 18: 600-9.
40. [40] Antoniou T, Tseng AL. Interactions between recreational drugs and antiretroviral agents. Annals Pharmacother 2002; 36(10): 1598-613.
41. [41] Uchaipichat V, Suthisisang C, Miners JO. The glucuronidation of R- and S-Lorazepam: human liver microsomal kinetics, UDPglucuronosyltransferase enzyme selectivity, and inhibition by drugs. Drug Metab Dispos 2013; 41(6): 1273-84.
42. [42] Meyer MR, Maurer HH. Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. Pharmacogenom 2011; 12(2): 215-33.
43. [43] Li YB, Coller JK, Hutchinson MR, Klein K, Zanger UM, Stanley NJ, et al. The CYP2B6*6 allele significantly alters the Ndemethylation of ketamine enantiomers in vitro. Drug Metab Dispos 2013; 41(6): 1264-72.
44. [44] Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Therapeut 2004; 76(3): 250-69.
45. [45] Leimanis E, Best BM, Atayee RS, Pesce AJ. Evaluating the relationship of methadone concentrations and EDDP formation in chronic pain patients. J Anal Toxicol 2012; 36(4): 239-49.
46. [46] Kharasch ED, Stubbert K. Role of cytochrome P4502B6 in methadone metabolism and clearance. J Clin Pharmacol 2013; 53(3): 305-13.
47. [47] Katoh M, Nakajima M, Yamazaki H, Yokoi T. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoproteinmediated transport. Eur J Pharm Sci 2001; 12(4): 505-13.
48. [48] Leslie EM, Deeley RG, Cole SP. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 2001; 167(1): 3-23.
49. [49] Pal D, Kwatra D, Minocha M, Paturi DK, Budda B, Mitra AK. Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals. Life Sci 2011; 88(21- 22): 959-71.
50. [50] EACS. European Guidelines for Treatment of HIV Infected Adults in Europe. Available at: http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EacsGuidelines-v6.1-2edition.pdf (Accessed on: July 16, 2013).
51. [51] Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. Jama 2010; 304(3): 321-33.
52. [52] McCance-Katz EF. Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents. Clin Infect Dise 2005; 41(Suppl 1): S89-95.
53. [53] McDowell JA, Chittick GE, Stevens CP, Edwards KD, Stein DS. Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2000; 44(6): 1686-90.
54. [54] Emtriva, E. Gilead Sciences Intl Ltd. Summary of product characteristics. US8598185B2 (2011).
55. [55] Unadkat JD, Crosby SS, Wang JP, Hertel CC. Simple and rapid high-performance liquid chromatographic assay for zidovudine (azidothymidine) in plasma and urine. J Chromatogr 1988; 430(2): 420-3.
56. [56] Viread, T.D.F. Gilead Sciences Intl Ltd. Summary of product characteristics. WO2006135933 A2 (2012).
57. [57] Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebocontrolled phase 3 trial. Lancet 2013; 381(9883): 2083-90.
58. [58] Zerit, S. Bristol-Myers Squibb Pharma EEIG. Summary of product characteristics. US8492386B2 (2012).
59. [59] Diana M. The addicted brain. Front Psychiat 2013; 4: 40.
60. [60] Baker J, Rainey PM, Moody DE, Morse GD, Ma Q, McCance-Katz EF. Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir. Am J Addictions/Am Acad Psychiatrists Alcoholism Addictions 2010; 19(1): 17-29.
61. [61] Smith PF, DiCenzo R, Morse GD. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokin 2001; 40(12): 893-905.
62. [62] Mouly S, Lown KS, Kornhauser D, Joseph JL, Fiske WD, Benedek IH, et al. Hepatic but not intestinal CYP3A4 displays dosedependent induction by efavirenz in humans. Clin Pharmacol Therapeut 2002; 72(1): 1-9.
63. [63] von Moltke LL, Greenblatt DJ, Granda BW, Giancarlo GM, Duan SX, Daily JP, et al. Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol 2001; 41(1): 85-91.
64. [64] McCance-Katz EF, Moody DE, Morse GD, Friedland G, Pade P, Baker J, et al. Interactions between buprenorphine and antiretrovirals: the nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin Infect Diseases 2006; 43(Suppl 4): S224-34.
65. [65] McCance-Katz EF, Gourevitch MN, Arnsten J, Sarlo J, Rainey P, Jatlow P. Modified directly observed therapy (MDOT) for injection drug users with HIV disease. Am J Addictions/Am Acad Psychiatrists Alcoholism Addictions 2002; 11(4): 271-8.
66. [66] Kharasch ED, Whittington D, Ensign D, Hoffer C, Bedynek PS, Campbell S, et al. Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics. Clin Pharmacol Therapeut 2012; 91(4): 673-84.
67. [67] Fellay J, Marzolini C, Decosterd L, Golay KP, Baumann P, Buclin T, et al. Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur J Clin Pharmacology 2005; 60(12): 865-73.
68. [68] Robertson SM, Maldarelli F, Natarajan V, Formentini E, Alfaro RM, Penzak SR. Efavirenz induces CYP2B6-Mediated hydroxylation of Bupropion in healthy subjects. Jaids-J Acquir Immune Defic Syndr 2008; 49(5): 513-9.
69. [69] Pelet A, Favrat B, Cavassini M, Eap CB, Besson J, Monnat M. Usefulness of methadone plasma concentration measurement in patients receiving nevirapine or efavirenz. Am J Drug Alcohol Abuse 2011; 37(4): 264-8.
70. [70] Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG, et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol 2001; 51(3): 213-7.
71. [71] Gatch MB, Kozlenkov A, Huang RQ, Yang W, Nguyen JD, Gonzalez-Maeso J, et al. The HIV antiretroviral drug efavirenz has LSD-like properties. Neuropsychopharmacology 2013; 38(12): 2373-84.
72. [72] Ma Q, Okusanya OO, Smith PF, Dicenzo R, Slish JC, Catanzaro LM, et al. Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Expert Opin Drug Metab Toxicol 2005; 1(3): 473-85.
73. [73] Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG, et al. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin Infect Diseases 2001; 33(9): 1595-7.
74. [74] McCance-Katz EF, Moody DE, Morse GD, Ma Q, Rainey PM. Lack of clinically significant drug interactions between nevirapine and buprenorphine. Am J Addictions/Am Acad Psychiatrists Alcoholism Addictions 2010; 19(1): 30-7.
75. [75] Kakuda TN, Scholler-Gyure M, Hoetelmans RMW. Pharmacokinetic interactions between Etravirine and nonantiretroviral drugs. Clin Pharmacokin 2011; 50(1): 25-39.
76. [76] Scholler-Gyure M, van den Brink W, Kakuda TN, Woodfall B, De Smedt G, Vanaken H, et al. Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers. J Clin Pharmacol 2008; 48(3): 322-9.
77. [77] Crauwels H, van Heeswijk RPG, Stevens M, Buelens A, Vanveggel S, Boven K, et al. Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor Rilpivirine. Aids Rev 2013; 15(2): 87-101.
78. [78] Crauwels HM, van Heeswijk RP, Vandevoorde A, Buelens A, Stevens M, Hoetelmans RM. The effect of rilpivirine on the pharmacokinetics of methadone in HIV-negative volunteers. J Clin Pharmacol 2013; 54(2): 133-40.
79. [79] Vourvahis M, Wang R, Gruener DM, Bruce RD, Haider S, Tawadrous M. Effect of lersivirine (UK-453,061) co-administration on the pharmacokinetics of methadone in healthy subjects. Abstract MOPE180, Meeting Report 6th IAS. Rome, 2011.
80. [80] Gandhi M, Benet LZ, Bacchetti P, Kalinowski A, Anastos K, Wolfe AR, et al. Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women. Jaids-J Acquir Immune Defic Syndr 2009; 50(5): 482-91.
81. [81] Juethner SN, Seyfried W, Aberg JA. Tolerance of efavirenzinduced central nervous system side effects in HIV-infected individuals with a history of substance abuse. HIV Clin Trials 2003; 4(3): 145-9.
82. [82] Kharasch ED, Hoffer C, Whittington D, Walker A, Bedynek PS. Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport insights from methadone interactions with Ritonavir/Indinavir. Anesthesiol 2009; 110(3): 660-72.
83. [83] Hendrix CW, Wakeford J, Wire MB, Lou Y, Bigelow GE, Martinez E, et al. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects. Pharmacotherapy 2004; 24(9): 1110-21.
84. [84] Hsyu PH, Lillibridge J, Daniels E, Kerr BM. Pharmacokinetic interaction of nelfinavir and methadone in intravenous drug users. Biopharm Drug Dispos 2006; 27(2): 61-8.
85. [85] Kharasch ED, Bedynek PS, Walker A, Whittington D, Hoffer C. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and Pglycoprotein activities. Clini Pharmacol Therapeut 2008; 84(4): 506-12.
86. [86] Gerber JG, Rosenkranz S, Segal Y, Aberg J, D'Amico R, Mildvan D, et al. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. J Acquir Immune Defic Syndr 2001; 27(2): 153-60.
87. [87] Aptivus, T. Boehringer Ingelheim Pharma GmbH & Co. Summary of product characteristics. WO2010039534A2 (2012).
88. [88] Hsu A, Granneman GR, Carothers L, Dennis S, Chiu Y-L, Valdes J, et al. Ritonavir does not increase methadone exposure in healthy volunteers. 5th Conference on Retroviruses and Opportunistic Infection. Chicago, Feb 1–5, 1998, abstract 342
89. [89] Norvir, R. Abbott Laboratories Ltd. Summary of product characteristics. WO2002096395A1 (2012).
90. [90] Luthi B, Huttner A, Speck RF, Mueller NJ. Methadone-induced Torsade de pointes after stopping lopinavir-ritonavir. Eur J Clin Microbiol Infect Dis 2007; 26(5): 367-9.
91. [91] McCance-Katz EF, Rainey PM, Friedland G, Jatlow P. The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin Infect Dis: Off Public Infect Dis Soc Am 2003; 37(4): 476-82.
92. [92] Clarke S, Mulcahy F, Bergin C, Reynolds H, Boyle N, Barry M, et al. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. Clin Infect Dis: Off Public Infect Dis Soc Am 2002; 34(8): 1143-5.
93. [93] Kharasch ED, Bedynek PS, Hoffer C, Walker A, Whittington D. Lack of Indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A). Anesthesiol 2012; 116(2): 432-47.
94. [94] Kharasch ED, Walker A, Whittington D, Hoffer C, Bedynek PS. Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug Alcohol Depend 2009; 101(3): 158-68.
95. [95] Friedland G, Andrews L, Schreibman T, Agarwala S, Daley L, Child M, et al. Lack of an effect of atazanavir on steady-state pharmacokineties of methadone in patients chronically treated for opiate addiction. AIDS 2005; 19(15): 1635-41.
96. [96] Totah RA, Sheffels P, Roberts T, Whittington D, Thummel K, Kharasch ED. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 2008; 108(3): 363-74.
97. [97] Kharasch ED, Mitchell D, Coles R, Blanco R. Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother 2008; 52(5): 1663-9.
98. [98] McCance-Katz EF, Moody DE, Morse GD, Ma Q, DiFrancesco R, Friedland G, et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend 2007; 91(2-3): 269-78.
99. [99] Piscitelli SC, Kress DR, Bertz RJ, Pau A, Davey R. The effect of ritonavir on the pharmacokinetics of meperidine and normeperidine. Pharmacotherapy 2000; 20(5): 549-53.
100. [100] Flexner CW, Cargill VA, Sinclair J, Kresina TF, Cheever L. Alcohol use can result in enhanced drug metabolism in HIV pharmacotherapy. AIDS Patient Care STDS 2001; 15(2): 57-8.
101. [101] Kresina TF, Flexner CW, Sinclair J, Correia MA, Stapleton JT, Adeniyi-Jones S, et al. Alcohol use and HIV pharmacotherapy. AIDS Res Hum Retroviruses 2002; 18(11): 757-70.
102. [102] Specka M, Heilmann M, Lieb B, Scherbaum N. Use of disulfiram for alcohol relapse prevention in patients in opioid maintenance treatment. Clin Neuropharmacol 2014; 37(6): 161-5.
103. [103] McCance-Katz EF, Gruber VA, Beatty G, Lum P, Ma Q, DiFrancesco R, et al. Interaction of disulfiram with antiretroviral medications: efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism. Am J Addictions/Am Acad Psychiatrists Alcoholism Addictions 2014; 23(2): 137-44.
104. [104] Greenblatt DJ, von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, et al. Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr 2000; 24(2): 129-36.
105. [105] Greenblatt DJ, von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, et al. Alprazolam-ritonavir interaction: implications for product labeling. Clin Pharmacol Therapeut 2000; 67(4): 335-41.
106. [106] Frye R, Bertz R, Granneman G, Qian J, Lamm J, Dennis S. Effect of ritonavir on the pharmacokinetics and pharmacodynamics of alprazolam (abstract A59). Proceedings of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 28– October 1, 1997.
107. [107] Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clin Pharmacol Therapeut 1999; 66(1): 33-9.
108. [108] Invirase, S.M. Roche Registration Ltd. Summary of product characteristics. EP2392926A1 (2012).
109. [109] Kaletra, L.W.R. Abbott Laboratories Ltd. Summary of product characteristics. US8691878B2 (2012).
110. [110] Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2010; 54(1): 254-8.
111. [111] Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metabol Dispos: Biol Fate Chem 2013; 41(2): 353-61.
112. [112] Cottrell ML, Hadzic T, Kashuba AD. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokin 2013; 52(11): 981-94.
113. [113] Song I, Mark S, Chen S, Savina P, Wajima T, Peppercorn A, et al. Dolutegravir does not affect methadone pharmacokinetics in opioid-dependent, HIV-seronegative subjects. Drug Alcohol Depend 2013; 133(2): 781-4.
114. [114] Cocohoba J, Dong BJ. Raltegravir: the first HIV integrase inhibitor. Clin Ther 2008; 30(10): 1747-65.
115. [115] Iwamoto M, Kassahun K, Troyer MD, Hanley WD, Lu P, Rhoton A, et al. Lack of a pharmacokinetic effect of raltegravir on midazolam: In vitro/in vivo correlation. J Clin Pharmacol 2008; 48(2): 209-14.
116. [116] Bruce RD, Moody DE, Chodkowski D, Andrews L, Fang WFB, Morrison J, et al. Pharmacokinetic interactions between Buprenorphine/Naloxone and raltegravir in subjects receiving chronic Buprenorphine/Naloxone treatment. Am J Drug Alcohol Abuse 2013; 39(2): 80-5.
117. [117] Ramanathan S, Mathias AA, German P, Kearney BP. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokin 2011; 50(4): 229-44.
118. [118] Klibanov OM. Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection. Curr Opin Investigat Drugs 2009; 10(2): 190-200.
119. [119] Lee JS, Calmy A, Andrieux-Meyer I, Ford N. Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings. HIV AIDS (Auckl) 2012; 4: 5-15.
120. [120] Bruce RD, Winkle P, Custodio JM, Wei LX, Rhee MS, Kearney BP, et al. The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment. J Acquir Immune Defic Syndr 2013; 63(4): 480-4.
121. [121] Bruce RD, Winkle P, Custodio JM, Wei X, Rhee MS, Kearney BP, et al. Investigation of the interactions between methadone and elvitegravir-cobicistat in subjects receiving chronic methadone maintenance. Antimicrob Agents Chemother 2013; 57(12): 6154-7.
122. [122] Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005; 11(11): 1170-2.
123. [123] Walker DK, Abel S, Comby P, Muirhead GJ, Nedderman AN, Smith DA. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos: Biol Fate Chem 2005; 33(4): 587-95.
124. [124] Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49(11): 4721-32.
125. [125] Celsentri, M. Summary of product characteristics. US8492386 B2 (2012).
126. [126] Abel S, Russell D, Whitlock LA, Ridgway CE, Muirhead GJ. Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers. Br J Clin Pharmacol 2008; 65(Suppl 1): 19-26.
127. [127] Patel IH, Zhang X, Nieforth K, Salgo M, Buss N. Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokin 2005; 44(2): 175-86.
128. [128] Zhang X, Lalezari JP, Badley AD, Dorr A, Kolis SJ, Kinchelow T, et al. Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients. Clin Pharmacol Therapeut 2004; 75(6): 558-68.
129. [129] Bachmann KA, Ghosh R. The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions. Curr Drug Metabol 2001; 2(3): 299-314.
130. [130] Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. Jama 2001; 286(18): 2270-9.
131. [131] Venkatakrishnan K, von Moltke LL, Obach RS, Greenblatt DJ. Drug metabolism and drug interactions: application and clinical value of in vitro models. Curr Drug Metabol 2003; 4(5): 423-59.
132. [132] De Fazio S, Gallelli L, De Siena A, De Sarro G, Scordo MG. Role of CYP3A5 in abnormal clearance of methadone. Ann Pharmacother 2008; 42(6): 893-7.
133. [133] Gallelli L, Colosimo M, Tolotta GA, Falcone D, Luberto L, Curto LS, et al. Prospective randomized double-blind trial of racecadotril compared with loperamide in elderly people with gastroenteritis living in nursing homes. Eur J Clin Pharmacol 2010; 66(2): 137-44.
134. [134] Gallelli L, Galasso O, Urzino A, Sacca S, Falcone D, Palleria C, et al. Characteristics and clinical implications of the pharmacokinetic profile of Ibuprofen in patients with knee osteoarthritis. Clin Drug Investig 2012; 32(12): 827-33.
135. [135] Pelaia G, Vatrella A, Gallelli L, Cazzola M, Maselli R, Marsico SA. Potential genetic influences on the response to asthma treatment. Pulm Pharmacol Ther 2004; 17(5): 253-61.
136. [136] Lang, T., Zanger, U.M. Polymorphisms in the human CYP2B6 gene and their use in diagnostic and therapeutic applications. WO2001059152A2 (2001).
137. [137] Sadee, W., Wang, D. Polymorphisms in genes affecting CYP2C9- related disorders and uses thereof. US20100129818A1 (2010).
138. [138] Andersson, M.K., Lewander, T., Oliasson, E., Risinger, C. Detection of CYP2C19 polymorphisms. WO2002018639A2 (2002).
139. [139] Huang, D. Identifying polymorphism in a gene by incubating a reaction comprising nucleic acid, polymerase, extension primers and labeled nucleotide triphosphates; allows tailoring of drug therapy based on the individuals metabolism. US20040091909A1 (2004).
140. [140] Sadee, W., Wang, D. Polymorphism in CYP3A4 gene affecting drug metabolizing and uses thereof. EP2411542A1 (2012).
141. [141] Wada, M., Kuwano, M. SNPs in 5’ regulatory region of MDR1 gene. WO2005028645A1 (2005)